Madrigal Pharmaceuticals Net Income
| MDGL Stock | USD 482.45 7.28 1.49% |
As of the 4th of February, Madrigal Pharmaceuticals secures the Mean Deviation of 2.1, downside deviation of 2.28, and Risk Adjusted Performance of 0.0682. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Madrigal Pharmaceuticals, as well as the relationship between them. Please verify Madrigal Pharmaceuticals treynor ratio, and the relationship between the standard deviation and downside variance to decide if Madrigal Pharmaceuticals is priced some-what accurately, providing market reflects its recent price of 482.45 per share. Given that Madrigal Pharmaceuticals has jensen alpha of 0.2131, we recommend you to check Madrigal Pharmaceuticals's last-minute market performance to make sure the company can sustain itself at a future point.
Madrigal Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 14.1388 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -419.3 M | -398.3 M | |
| Net Loss | -419.3 M | -398.3 M | |
| Net Loss | -265.8 M | -252.5 M | |
| Net Loss | (19.71) | (20.70) | |
| Net Income Per E B T | 0.90 | 0.54 |
Madrigal | Net Income | Build AI portfolio with Madrigal Stock |
Historical Net Income data for Madrigal Pharmaceuticals serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Madrigal Pharmaceuticals represents a compelling investment opportunity.
Latest Madrigal Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Madrigal Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Madrigal Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Madrigal Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Madrigal Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Madrigal Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (465.89 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Madrigal Net Income Regression Statistics
| Arithmetic Mean | (167,526,372) | |
| Coefficient Of Variation | (97.65) | |
| Mean Deviation | 143,335,277 | |
| Median | (86,161,000) | |
| Standard Deviation | 163,594,044 | |
| Sample Variance | 26763T | |
| Range | 465.5M | |
| R-Value | (0.87) | |
| Mean Square Error | 6764T | |
| R-Squared | 0.76 | |
| Slope | (28,299,363) | |
| Total Sum of Squares | 428208.2T |
Madrigal Net Income History
Other Fundumenentals of Madrigal Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Madrigal Pharmaceuticals Net Income component correlations
Madrigal Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Madrigal Pharmaceuticals is extremely important. It helps to project a fair market value of Madrigal Stock properly, considering its historical fundamentals such as Net Income. Since Madrigal Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Madrigal Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Madrigal Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. Expected growth trajectory for Madrigal significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Madrigal Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (12.90) | Revenue Per Share | Quarterly Revenue Growth 3.62 | Return On Assets | Return On Equity |
Investors evaluate Madrigal Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Madrigal Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Madrigal Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Madrigal Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Madrigal Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Madrigal Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Madrigal Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Madrigal Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Madrigal Pharmaceuticals.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Madrigal Pharmaceuticals on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Madrigal Pharmaceuticals or generate 0.0% return on investment in Madrigal Pharmaceuticals over 90 days. Madrigal Pharmaceuticals is related to or competes with Avidity Biosciences, Jazz Pharmaceuticals, Moderna, Caris Life, Rhythm Pharmaceuticals, Abivax SA, and Bio Techne. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercializa... More
Madrigal Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Madrigal Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Madrigal Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.28 | |||
| Information Ratio | 0.065 | |||
| Maximum Drawdown | 16.78 | |||
| Value At Risk | (3.26) | |||
| Potential Upside | 7.29 |
Madrigal Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Madrigal Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Madrigal Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Madrigal Pharmaceuticals historical prices to predict the future Madrigal Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0682 | |||
| Jensen Alpha | 0.2131 | |||
| Total Risk Alpha | 0.0623 | |||
| Sortino Ratio | 0.0854 | |||
| Treynor Ratio | 0.413 |
Madrigal Pharmaceuticals February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0682 | |||
| Market Risk Adjusted Performance | 0.423 | |||
| Mean Deviation | 2.1 | |||
| Semi Deviation | 2.02 | |||
| Downside Deviation | 2.28 | |||
| Coefficient Of Variation | 1209.48 | |||
| Standard Deviation | 3.0 | |||
| Variance | 8.99 | |||
| Information Ratio | 0.065 | |||
| Jensen Alpha | 0.2131 | |||
| Total Risk Alpha | 0.0623 | |||
| Sortino Ratio | 0.0854 | |||
| Treynor Ratio | 0.413 | |||
| Maximum Drawdown | 16.78 | |||
| Value At Risk | (3.26) | |||
| Potential Upside | 7.29 | |||
| Downside Variance | 5.21 | |||
| Semi Variance | 4.07 | |||
| Expected Short fall | (2.53) | |||
| Skewness | 0.9834 | |||
| Kurtosis | 2.14 |
Madrigal Pharmaceuticals Backtested Returns
As of now, Madrigal Stock is very steady. Madrigal Pharmaceuticals has Sharpe Ratio of close to zero, which conveys that the firm had a close to zero % return per unit of risk over the last 3 months. We have found twenty-seven technical indicators for Madrigal Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please verify Madrigal Pharmaceuticals' Mean Deviation of 2.1, risk adjusted performance of 0.0682, and Downside Deviation of 2.28 to check out if the risk estimate we provide is consistent with the expected return of 0.0168%. The company secures a Beta (Market Risk) of 0.58, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Madrigal Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Madrigal Pharmaceuticals is expected to be smaller as well. Madrigal Pharmaceuticals right now secures a risk of 2.8%. Please verify Madrigal Pharmaceuticals information ratio, downside variance, price action indicator, as well as the relationship between the treynor ratio and kurtosis , to decide if Madrigal Pharmaceuticals will be following its current price movements.
Auto-correlation | -0.73 |
Almost perfect reverse predictability
Madrigal Pharmaceuticals has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Madrigal Pharmaceuticals time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Madrigal Pharmaceuticals price movement. The serial correlation of -0.73 indicates that around 73.0% of current Madrigal Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.73 | |
| Spearman Rank Test | -0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 2042.08 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Madrigal Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Madrigal Pharmaceuticals reported net income of (465.89 Million). This is 236.51% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 181.6% higher than that of the company.
Madrigal Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Madrigal Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Madrigal Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Madrigal Pharmaceuticals by comparing valuation metrics of similar companies.Madrigal Pharmaceuticals is currently under evaluation in net income category among its peers.
Madrigal Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Madrigal Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Madrigal Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Madrigal Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Madrigal Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Madrigal Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Madrigal Pharmaceuticals' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 414.4 K | Adage Capital Partners Gp Llc | 2025-06-30 | 376.2 K | William Blair Investment Management, Llc | 2025-06-30 | 350.3 K | Bank Of America Corp | 2025-06-30 | 277.2 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 248 K | Hood River Capital Management Llc | 2025-06-30 | 244.7 K | Polar Capital Holdings Plc | 2025-06-30 | 225.4 K | Pictet Asset Manangement Sa | 2025-06-30 | 208.3 K | Citadel Advisors Llc | 2025-06-30 | 207.3 K | Hhg Plc | 2025-06-30 | 2.2 M | Paulson & Company Inc | 2025-06-30 | 2.1 M |
Madrigal Fundamentals
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.39) % | ||||
| Operating Margin | (0.40) % | ||||
| Current Valuation | 10.47 B | ||||
| Shares Outstanding | 22.71 M | ||||
| Shares Owned By Insiders | 7.66 % | ||||
| Shares Owned By Institutions | 92.34 % | ||||
| Number Of Shares Shorted | 3.86 M | ||||
| Price To Earning | (13.96) X | ||||
| Price To Book | 17.96 X | ||||
| Price To Sales | 15.02 X | ||||
| Revenue | 180.13 M | ||||
| Gross Profit | 705.49 M | ||||
| EBITDA | (450.12 M) | ||||
| Net Income | (465.89 M) | ||||
| Cash And Equivalents | 211.77 M | ||||
| Cash Per Share | 12.38 X | ||||
| Total Debt | 119.57 M | ||||
| Debt To Equity | 0.59 % | ||||
| Current Ratio | 2.55 X | ||||
| Book Value Per Share | 27.56 X | ||||
| Cash Flow From Operations | (455.57 M) | ||||
| Short Ratio | 11.44 X | ||||
| Earnings Per Share | (12.90) X | ||||
| Target Price | 657.13 | ||||
| Number Of Employees | 528 | ||||
| Beta | -1.02 | ||||
| Market Capitalization | 11.12 B | ||||
| Total Asset | 1.04 B | ||||
| Retained Earnings | (1.8 B) | ||||
| Working Capital | 863.65 M | ||||
| Current Asset | 363.58 K | ||||
| Current Liabilities | 49.28 M | ||||
| Net Asset | 1.04 B |
About Madrigal Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Madrigal Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Madrigal Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Madrigal Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. Expected growth trajectory for Madrigal significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Madrigal Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (12.90) | Revenue Per Share | Quarterly Revenue Growth 3.62 | Return On Assets | Return On Equity |
Investors evaluate Madrigal Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Madrigal Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Madrigal Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Madrigal Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Madrigal Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Madrigal Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.